INmune Bio, Inc.INMBNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -15.80% |
| Q2 2025 | -24.02% |
| Q1 2025 | 3.89% |
| Q4 2024 | -26.96% |
| Q3 2024 | 42.73% |
| Q2 2024 | -18.87% |
| Q1 2024 | 44.71% |
| Q4 2023 | 0.37% |
| Q3 2023 | 44.29% |
| Q2 2023 | 0.36% |
| Q1 2023 | 21.20% |
| Q4 2022 | -33.90% |
| Q3 2022 | 23.16% |
| Q2 2022 | -2.78% |
| Q1 2022 | -39.04% |
| Q4 2021 | 8.40% |
| Q3 2021 | 46.06% |
| Q2 2021 | 79.21% |
| Q1 2021 | 34.00% |
| Q4 2020 | -21.33% |
| Q3 2020 | 161.67% |
| Q2 2020 | 13.91% |
| Q1 2020 | -8.51% |
| Q4 2019 | -25.81% |
| Q3 2019 | 297.53% |
| Q2 2019 | 189.21% |
| Q1 2019 | -80.28% |
| Q4 2018 | 159.23% |
| Q3 2018 | -30.82% |
| Q2 2018 | 176.24% |
| Q1 2018 | -61.24% |
| Q4 2017 | 479.35% |
| Q3 2017 | -28.67% |
| Q2 2017 | 12.68% |
| Q1 2017 | 104.61% |
| Q4 2016 | 2.18% |
| Q3 2016 | 0.00% |